Trial Profile
Predictors of clinical response to Ipilimumab, in patients with melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 17 Jul 2015 New trial record
- 02 Jun 2015 Interim results (n=10; Baseline serum predictors of clinical response) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.